Those Eureka Moments Glisten: A Conversation With Robert A. Weinberg, PhD
When Robert A. Weinberg was a boy, he loved dissecting what was complicated and figuring out what made it work.
Building Blocks of a Biotech: CytRx Executives Talk About 3 Agents for Multiple Tumors
Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.
JAK-STAT Signaling Has Many Faces: Inhibitors Offer Hope in Rare Blood Cancers
Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.
3 Questions for Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.
Novel Therapies Usher in New Era
Every decade during the past 50 years, treatment for multiple myeloma has taken a leap forward.
Ruxolitinib Results Promising in 2 Myelofibrosis Studies
Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.
Looking Before Leaping: When to Change Practice Based on ASCO Results
Which studies should influence how I manage my patients and what criteria should I use to make these decisions?
Interim Safety Data Compared in Ixabepilone TITAN Trial
Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).
Game-Changers: 11 Key Abstracts in ASCO Lineup
Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.
5 Abstracts Offer Snapshot of Immunology Research
The field of immunotherapy is brimming with questions that researchers are working to answer, and many of those efforts were on display at the ASCO annual meeting.
Aiming for Immunity: New Therapies in Sights
Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512